DexCom Inc.
DXCM | NASDAQ
$82.29
$0.00 (0.00%)
Nov 2, 2026, 9:30 AM ET · Market open
Company Profile
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Jacob Steven Leach | President, CEO & Director |
| Peter Simpson | Executive Vice President & Chief Technology Officer |
| Christine Pospisil | Director of Medical Science & Education |
| Jereme Sylvain | Executive VP, CFO, COO & Chief Accounting Officer |
| Jon Coleman | Executive Vice President & Chief Commercial Officer |
| Keri Leone | Senior Director of Global Medical Science & Education |
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Matthew Dolan | Executive Vice President of Strategy & Corporate Development |
| Michael Brown | Executive VP, Chief Legal & Compliance Officer |
| Sadie Stern | Executive VP, Chief People & Culture Officer |
| Sean Christensen | Vice President of Finance and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 3 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
DexCom Inc.
| Country | United States |
| IPO Date | Apr 14, 2005 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 11,050 |
| CEO | Jacob Steven Leach |
Contact Details
6340 Sequence Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | DXCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001093557 |
| CUSIP Number | 252131107 |
| ISIN Number | US2521311074 |
| SIC Code | 3841 |
Recent News
- 15 hours ago / seekingalpha.comDexCom: Improving Patient Access Makes It A Long-Term Buy
- 3 days ago / zacks.comDexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
- 3 days ago / seekingalpha.comDexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
- 3 days ago / marketbeat.comWhat DexCom (DXCM) Said on Its Q3 Earnings Call
- 3 days ago / zacks.comDexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
- 3 days ago / benzinga.comDexCom Q3 2026 Earnings Call Transcript
- 3 days ago / investors.comDiabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
- 3 days ago / businesswire.comDexcom Reports Third Quarter 2026 Financial Results
- 5 days ago / businesswire.comDexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- 5 days ago / prnewswire.comDid DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Add to Watchlist
Select watchlists to add or remove DXCM